GlaxoSmithkline:
GSK at International Aids Conference, August 13-19, Toronto Canada.
GSK positive Action was a principal offer of a global village at the AIDS international conference in Toronto Canada. The global village was an interactive and participatory community space at the that aimed to engange, challenge and inspire. it was the first point of contact for delegates as they entered the conference venue each day and it was also open to the public.
In addition, to support the global village, GSK hosted a number of community forums and skills-building workshops where community delegates could share experiences, learning from each other and from experts to increase their effectiveness and ability to respond to challenging epidemics and socio-political environment.
Together with partner organizations like NAM and Action Traitements, GSK was on hand at their shared treatment and literacy booth in the global village exhibition area demonstrating a variety of on-line resources in the several languages.
Monday, 24 September 2007
Thursday, 20 September 2007
Global Business
Glaxosmithkline and Sepracor Inc. announced an agreement for the commercialization of Sepracor's eszopiclone product for all markets worldwide (excluding US, Mexico, Canada and Japan).
Adrian Adams, President and C.E.O of Sepracor said that, "GSK is one of the worlds largest pharmaceutical companies and we are delighted to have established this alliance with such a renowned organisation that has a strong presence in the European Union and other global markets."
Adrian Adams, President and C.E.O of Sepracor said that, "GSK is one of the worlds largest pharmaceutical companies and we are delighted to have established this alliance with such a renowned organisation that has a strong presence in the European Union and other global markets."
Tuesday, 18 September 2007
week 4 assignmnt
Glaxosmithkline recently advertised 'Avandia' the most widely studied oral anti-diabetic medicine for tretment of type 2 diabetes. The advertisement includes scientific evidence available to address the question of side effects. The extensive data includes 166 clinical trials in over 52,000 patients. These includes:
Heart attack -the number of heart attacks across all sources of data is small
CV death - the long term trials provide no evidence of increased cv death
Stroke - fewer strokes are observed with 'Avandia' than with other anti-diabetic medicines
Heart attack -the number of heart attacks across all sources of data is small
CV death - the long term trials provide no evidence of increased cv death
Stroke - fewer strokes are observed with 'Avandia' than with other anti-diabetic medicines
Thursday, 13 September 2007
week 3 assignment
The stock market did not signifcantly affect my United Kingdom Company based Pharmaceutical company, Glaxosmithkline, last week. However, the staistics were as follows:
Last Trade NYSE close Change Volume
54.08 54.08 +0.36(+0.67%) 1289.500
As of close of the week volume was 2,989,739,000
NYSE Composite 9678.12 79.39^
Dow Jones Inc 13424.88 133.23^
Last Trade NYSE close Change Volume
54.08 54.08 +0.36(+0.67%) 1289.500
As of close of the week volume was 2,989,739,000
NYSE Composite 9678.12 79.39^
Dow Jones Inc 13424.88 133.23^
Subscribe to:
Posts (Atom)